[1] Ge YH, Li QQ , Wang CG, et al. The role of IL22 polymorphisms on liver cirrhosis in patients with hepatitis B virus: A case control study. Medicine, 2019, 98(44):e17867.
[2] Lin CL, TsengKC , Chen KY, et al. Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy. J Formos Med Assoc, 2020,119(10):1483-1489.
[3] Ho CH, Chang TT,Chien RN. Telbivudine on IgG-associated hypergammaglobulinemia and TGF-β1 hyperactivity in hepatitis B virus-related liver cirrhosis. PLoS One, 2019,14(11):e0225482.
[4] Yuan L, Jing J,Xuan L, et al. HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation. Gut,2019,68(11):2044-2056.
[5] Pralle RS , Erb SJ , Holdorf HT, et al. Greater liver PNPLA3 protein abundance in vivo and in vitro supports lower triglyceride accumulation in dairy cows. Sci Rep,2021,11(1):233-240.
[6] Li XX, Lu XY, Zhang SJ, et al. Sodiumtanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation. Biomed Pharmacother,2019,111(3):68-75.
[7] 中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):V-XVI.
[8] 中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南.中华肝脏病杂志,2006,14(11):866-870.
[9] 徐小元,丁惠国,李文刚,等.肝硬化诊治指南.实用肝脏病杂,2019,22(6):18-34.
[10] Deng YD,Peng XB,Zhao RR, et al. The intestinal microbial community dissimilarity in hepatitis B virus-related liver cirrhosis patients with and without at alcohol consumption. Gut Pathog,2019,11(1):58.
[11] 李莹,廖宇圣,孙圣斌,等.血清IL-17与IL-17-197A/G位点单核苷酸多态性和乙型病毒性肝炎易感性研究.中华医院感染学杂志,2020,30(11):1647-1650.
[12] Yang J,Trepo E,Nahon P, et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. Int J Cancer,2019,144(3):533-544.
[13] 邴浩,王薇,李异玲.中国东北地区汉族人群PNPLA3 rs738409及TM6SF2 rs58542926基因多态性与原发性肝癌的相关性.中华肝脏病杂志,2021,29(2):156-162.
[14] Caon E, Levi A, Dong X, et al. Analysis of PNPLA3 SNP variants in human hepatic stellate cells in 3D human liver extracellular matrix scaffolds reveals key PNPLA3-dependent pro-fibrogenic features. J Hepatol, 2020,73(8):S513.
[15] DaiGG,Liu PF, Li XY,et al. Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis. Medicine, 2019,98(7):e14324.
[16] Vilar-Gomez E , Pirola CJ, Sookoian S, et al. Impact of the association between PNPLA3 genetic variation and dietary intake on the risk of significant fibrosis in patients with NAFLD. Am J Gastroenterol, 2020,116(5):994-1006.
[17] Capone F,Vincentis AD, Ferraro E, et al. The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon. Clin Neurol Neurosurg, 2020, 197(8):106166.
[18] 于海兵,饶佳为,徐霖,等.广东省汉族人群PRKAA1基因rs249429和rs3805486位点单核苷酸多态性与2型糖尿病遗传易感性的关联研究.中国慢性病预防与控制,2021,29(7):513-517.
[19] Yan C, Zhu M, Ding Y, et al. Meta-analysis of genome-wide association studies and functional assays decipher susceptibility genes for gastric cancer in Chinese populations. Gut, 2019,69(4):641-651.
[20] Dargiene G, Streleckiene G, Skieceviciene J, et al. TLR1 and PRKAA1 gene polymorphisms in the development of atrophic gastritis and gastric cancer. J Gastrointestin Liver Dis,2018,27(4):363-369. |